Anti-aging composition, and preparation method therefor and use thereof

Abstract

The invention discloses an anti-aging composition as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 10 to 50 parts of ergothioneine; 5 to 25 parts of coenzyme Q10; 50 to 150 parts of 3-SL; 50 to 150 parts of collagen tripeptide; 100 to 500 parts of NAD (nicotinamide adenine dinucleotide); and 50 to 150 parts of glutathione. According to the anti-aging composition disclosed by the invention, various functional components such as the ergothioneine, the coenzyme Q10, the 3SL, the collagen tripeptide, the NAD < + > and the glutathione are reasonably proportioned, so that the anti-aging composition shows a remarkable synergistic anti-aging effect in in-vitro and in-vivo experiments. The anti-aging composition can enhance the cell antioxidant capacity, reduce the active oxygen level and promote the expression of collagen I and SIRT1, and compared with a single component or a non-optimized combination, the anti-aging effect is remarkably improved.

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202511917230.9 (22) Application Date 2025.12.18 (66) Domestic Priority Data 202511571772.5 2025.10.30 CN (71) Applicant Shenzhen Ruidelin Biotechnology Co., Ltd. Address 518100, 3rd Floor, Building 2, Shenzhen Biological Incubation Base, No. 10, Gaoxin Middle Road 1, Maling Community, Yuehai Street, Nanshan District, Shenzhen, Guangdong Province (72) Inventors Pan Junfeng Liu Jian (74) Patent Agency Shenzhen Zhiqu Intellectual Property Agency (General Partnership) 44486 Patent Attorney Liu Ting (51) Int.Cl. A61K 38 / 06 (2006.01) A61K 38 / 39 (2006.01) A61P 39 / 06(2006.01) A23L 33 / 10(2016.01) A23L 33 / 18(2016.01) A23L 33 / 17(2016.01) A23L 33 / 13(2016.01) A61K 31 / 4172(2006.01) A61K 31 / 122(2006.01) A61K 31 / 702(2006.01) A61K 31 / 7084(2006.01) (54) Invention Title: An anti-aging composition, its preparation method and application (57) Abstract: This invention discloses an anti-aging composition, its preparation method and application. The composition, by weight, comprises: 10-50 parts ergothioneine; 5-25 parts coenzyme Q10; 50-150 parts 3-SL; 50-150 parts collagen tripeptide; 100-500 parts NAD+; and 50-150 parts glutathione. The anti-aging composition of this invention, through a rational ratio of multiple functional components such as ergothioneine, coenzyme Q10, 3-SL, collagen tripeptide, NAD+, and glutathione, exhibits significant synergistic anti-aging effects in in vitro and in vivo experiments. The anti-aging composition of this invention can enhance cellular antioxidant capacity, reduce reactive oxygen species levels, and promote the expression of collagen I and SIRT1, significantly improving the anti-aging effect compared to single components or non-optimized combinations. Claims 1 page, Description 15 pages, Drawings 3 pages, CN 121422187 A 2026.01.30 CN 1 21 42 21 87 A 1. An anti-aging composition, characterized in that, by weight, it comprises the following components: Ergothioneine 5-80 parts; Coenzyme Q10 1-40 parts; 3-SL 30-200 parts; Collagen tripeptide 30-200 parts; NAD+ 50-600 parts; Glutathione 30-200 parts.2. The composition according to claim 1, characterized in that, by weight, the composition comprises the following components: 10-50 parts of ergothioneine; 5-25 parts of coenzyme Q10; 50-150 parts of 3-SL; 50-150 parts of collagen tripeptide; 100-500 parts of NAD+; and 50-150 parts of glutathione. 3. The composition according to claim 1, characterized in that, by weight, the composition comprises the following components: 25 parts of ergothioneine, 25 parts of coenzyme Q10, 75 parts of 3-SL, 110 parts of collagen tripeptide, 160 parts of NAD+, and 80 parts of glutathione. 4. The composition according to claim 1, characterized in that, by weight, the composition comprises the following components: 10 parts of ergothioneine, 25 parts of coenzyme Q10, 75 parts of 3-SL, 75 parts of collagen tripeptide, 250 parts of NAD+, and 80 parts of glutathione. 5. The composition according to claim 1, characterized in that, by weight, the composition comprises the following components: 10 parts ergothioneine, 50 parts coenzyme Q10, 20 parts 3-SL, 75 parts collagen tripeptide, 160 parts NAD+, and 80 parts glutathione. 6. The composition according to claim 1, characterized in that, by weight, the composition comprises the following components: 50 parts ergothioneine, 50 parts coenzyme Q10, 20 parts 3-SL, 110 parts collagen tripeptide, 160 parts NAD+, and 80 parts glutathione. 7. The composition according to claim 1, characterized in that the composition is any one of an oral liquid formulation, capsule, granule, tablet, or lyophilized powder dosage form. 8. The composition according to claim 1, characterized in that the composition further comprises any one or more of excipients, stabilizers, antioxidants, solubilizers, or buffers. 9. A method for preparing the composition according to any one of claims 1 to 8, characterized in that it comprises the following steps: weighing each component according to weight parts, adding an appropriate amount of purified water, magnetically stirring or ultrasonically mixing until completely dissolved, to obtain the composition solution. 10. The application of the composition according to any one of claims 1 to 8 in the preparation of anti-oxidative or anti-aging products. Claims 1 / 1 page 2 CN 121422187 A Anti-aging Composition and its Preparation Method and Application Technical Field

[0001] This invention relates to the field of anti-aging health products technology, and particularly to an anti-aging composition and its preparation method and application. Background Art

[0002] Aging is a natural physiological process of the human body, accompanied by various manifestations such as decreased skin elasticity, wrinkle formation, collagen loss, decreased antioxidant capacity, and weakened cell function. Aging not only affects appearance, but may also cause changes in the body's metabolism, immunity, and nerve function, becoming an important factor affecting overall health. With the changes in modern lifestyles and environmental factorsThe effects of aging, including skin problems, tissue degeneration, and free radical accumulation, are becoming increasingly prominent in people of all ages, and have become a widely concerned health issue in the fields of nutrition, health care, and beauty. Although various intervention methods have emerged in existing technologies to improve aging, there are still significant limitations. On the one hand, existing formulations or health care methods are mostly focused on a single pathway or a single target, making it difficult to simultaneously address multiple aspects such as oxidative stress, collagen loss, cell function decline, and tissue structure degeneration. On the other hand, there is a lack of systematic research on the ratio, dosage form, and stability of different active substances, and their activity is prone to decline during long-term storage and use, with uncertainties in in vitro and in vivo effects, making it difficult to achieve a sustained and stable anti-aging effect.

[0003] To ensure the long-term stability of the formulation, existing technologies usually require the addition of preservatives, antioxidants, or other chemical stabilizers. However, these additives may bring certain risks or limitations in long-term use: some preservatives may cause irritation or allergic reactions in sensitive individuals, reducing the safety and tolerability of the product; antioxidants or chemical stabilizers may affect the bioavailability of active ingredients at high concentrations or under long-term effects, or even trigger chemical degradation or side reactions. Furthermore, the presence of additives increases the complexity of the formulation, places higher demands on the production process, and may limit the choice of dosage form and application scenarios.

[0004] Therefore, there is an urgent need in the prior art for a composition that can achieve comprehensive anti-aging effects while ensuring the long-term stability of active ingredients, in order to overcome the problems of limited single-target intervention effects, unstable activity, and risks brought by additives. Summary of the Invention

[0005] In view of the deficiencies in the prior art, the present invention proposes an anti-aging composition, its preparation method, and its application.

[0006] The present invention provides an anti-aging composition comprising, by weight, the following components: 5-80 parts of ergothioneine (e.g., 5, 10, 20, 30, 40, 50, 60, 70, 80 parts, etc.); 1-40 parts of coenzyme Q10 (e.g., 1, 3, 5, 10, 15, 20, 25, 30, 35, 40 parts, etc.); 30-200 parts of 3-SL (e.g., 30, 40, 50, 100, 150, 200 parts, etc.); 30-200 parts of collagen tripeptide (e.g., 30, 40, 50, 100, 150, 200 parts, etc.); and 50-600 parts of NAD+ (e.g., 50, 100, 200, 300, 400, 500, 600 parts, etc.). Glutathione 30-200 parts (30, 50, 100, 150, 200 parts, etc.).

[0007] In some embodiments, the composition comprises, by weight, the following components: Ergothioneine 10-50 parts (e.g., 10, 20, 30, 40, 50 parts, etc.); Coenzyme Q10 5-25 parts (e.g., 5, 10, 15, 20, 25 parts, etc.); Specification 1 / 15 page 3 CN 121422187 A 3-SL50-150 parts (e.g., 50, 100, 150 parts, etc.); 50-150 parts collagen tripeptide (e.g., 50, 100, 150 parts, etc.); 100-500 parts NAD+ (e.g., 100, 200, 300, 400, 500 parts, etc.); 50-150 parts glutathione (e.g., 50, 100, 150 parts, etc.).

[0008] In some embodiments, the composition, by weight, comprises the following components: 25 parts ergothioneine, 25 parts coenzyme Q10, 75 parts 3-SL, 110 parts collagen tripeptide, 160 parts NAD+, and 80 parts glutathione.

[0009] In some embodiments, the composition comprises, by weight, the following components: 10 parts ergothioneine, 25 parts coenzyme Q10, 75 parts 3-SL, 75 parts collagen tripeptide, 250 parts NAD+, and 80 parts glutathione.

[0010] In some embodiments, the composition comprises, by weight, the following components: 10 parts ergothioneine, 50 parts coenzyme Q10, 20 parts 3-SL, 75 parts collagen tripeptide, 160 parts NAD+, and 80 parts glutathione.

[0011] In some embodiments, the composition comprises, by weight, the following components: 50 parts ergothioneine, 50 parts coenzyme Q10, 20 parts 3-SL, 110 parts collagen tripeptide, 160 parts NAD+, and 80 parts glutathione.

[0012] The above-mentioned formulation was obtained through in vitro screening and in vivo experiments and can maximize the synergistic effect between the components, improve antioxidant capacity and collagen expression.

[0013] In some embodiments, the composition is any one of oral liquid formulation, capsule, granule, tablet or lyophilized powder dosage form. Different dosage forms can be selected according to the usage scenario, stability requirements or individual needs, and ensure that the active ingredients remain stable during storage and administration.

[0014] In some embodiments, the composition further includes any one or more of excipients, stabilizers, antioxidants, solubilizers or buffers. These are used to improve the physicochemical properties of the formulation, improve solubility or prolong storage stability. The type and amount of the additives can be optimized according to the specific dosage form and active ingredient characteristics of the formulation.

[0015] The present invention also provides a method for preparing the composition, comprising the following steps: weighing each component according to the weight parts, adding an appropriate amount of purified water, magnetically stirring or ultrasonically mixing until completely dissolved, to obtain the composition solution.

[0016] The present invention also provides the application of the composition in the preparation of antioxidant or anti-aging products.

[0017] In some embodiments, the product is a drug, health product, or food.

[0018] In summary, compared with the prior art, the present invention achieves the following technical effects: 1. The anti-aging composition of the present invention, through a reasonable ratio of ergothioneine, coenzyme Q10, 3SL, collagen tripeptide, and NAD+, achieves the following effects:Including glutathione and other functional components, it can significantly improve the antioxidant capacity of cells, reduce the level of reactive oxygen species, and promote the expression of collagen I and SIRT1 in in vitro and in vivo experiments, thereby effectively exerting anti-aging effects. Compared with single components or ordinary compositions, the composition of the present invention exhibits a stronger synergistic effect, which can enhance the antioxidant and repair functions of skin and cells.

[0019] 2. The composition of the present invention has good physicochemical stability and bioactivity stability. Even without the addition of preservatives or antioxidant additives, it can maintain the stability and antioxidant activity of the main active ingredients for a long time, making it suitable for long-term storage and industrial production applications. Its multi-component synergistic stability characteristics make the composition of the present invention have significant advantages and broad application prospects in anti-aging, skin improvement and related health care applications. Brief Description of the Drawings

[0020] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention, and therefore should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort. Instruction Manual 2 / 15 Page 4 CN 121422187 A

[0021] Figure 1 shows the statistical results of ROS inhibition rate in Example 1 of the present invention.

[0022] Figure 2 shows the statistical results of SOD level in Example 3 of the present invention.

[0023] Figure 3 shows the statistical results of MAD level in Example 3 of the present invention.

[0024] Figure 4 shows the statistical results of GSH level in Example 3 of the present invention.

[0025] Figure 5 shows the statistical results of CAT level in Example 3 of the present invention.

[0026] Figure 6 shows the statistical results of melanin index (MI) and heme index (EI) in Example 4 of the present invention. Detailed Description

[0027] In order to enable those skilled in the art to better understand the present invention, the technical solutions in the embodiments of the present invention are clearly and completely described. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative labor should fall within the scope of protection of the present invention.

[0028] Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods. Unless otherwise specified, all materials and reagents used in this invention can be obtained commercially.

[0029] The raw materials used in this invention are sourced as follows: Quercetin was purchased from Beijing Yita Biotechnology; Resveratrol was purchased from Shanghai Hongshun Biotechnology; L-carnitine was purchased from Wuhan Fulin Biotechnology; Vitamin C was purchased from Qiyuan; Tea polyphenols were purchased from Beijing Naphthalene Biochemical; Ergothioneine was purchased from Shenzhen Ruidelin Biotechnology Co., Ltd.; Coenzyme Q10 was purchased from Shenzhen Ruidelin Biotechnology Co., Ltd.; 3-sialic acid lactose oligosaccharide was purchased from Shenzhen Ruidelin Biotechnology Co., Ltd.Collagen tripeptide was purchased from Shenzhen Ruidelin Biotechnology Co., Ltd.; NAD+ was purchased from Shenzhen Ruidelin Biotechnology Co., Ltd.; glutathione was purchased from Shenzhen Ruidelin Biotechnology Co., Ltd.

[0030] It should be noted that the above raw materials are all commercially available products commonly used in the field, and the public can obtain them from any conventional commercial channels. The present invention does not limit their source.

[0031] Example 1 Screening of active ingredients in anti-aging composition Raw material selection and grouping: In this example, quercetin, resveratrol, L-carnitine, vitamin C, tea polyphenols, ergothioneine, coenzyme Q10, 3-SL (3-sialic acid lactose oligosaccharide), collagen tripeptide, NAD+ (nicotinamide adenine dinucleotide), glutathione and other 11 components were selected for screening and analysis in different ratios.

[0032] The in vitro concentration range was converted from the physiological or supplement concentration range and the daily human intake dose as follows: Ergothioneine: 10~50 mg / mL.

[0033] Coenzyme Q10: 5~25 mg / mL.

[0034] 3-SL: 50~150 mg / mL.

[0035] Collagen tripeptide: 50~150 mg / mL.

[0036] NAD+: 100~500 mg / mL.

[0037] Glutathione: 50~150 mg / mL.

[0038] Quercetin: 5~20 mg / mL.

[0039] Resveratrol: 5~20 mg / mL.

[0040] L-carnitine: 50~200 mg / mL.

[0041] Vitamin C: 50~200 mg / mL.

[0042] Tea polyphenols: 50~150 mg / mL. Instruction manual 3 / 15 page 5 CN 121422187 A

[0043] The experimental group design is shown in Table 1, the unit is mg / mL: Table 1 Experimental group design Instruction manual 4 / 15 page 6 CN 121422187 A

[0044] Each of the above groups does not contain any excipients, carriers or additives, and each component is mixed in pure form. The mixing process is only achieved by physical means to achieve uniform dispersion. Then, each group solution is prepared with sterile deionized water.

[0045] Normal human fibroblasts (NHDF, Lonza) were selected as experimental models. The cells were seeded in 96-well plates at a seeding density of 1×104 cells per well. DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin was used. The cells were cultured in a constant temperature incubator at 37°C and 5% CO2 for 24 h to allow the cells to adhere stably and grow.

[0046] The experiment was divided into a blank group and an experimental group: the blank group was given an equal volume of deionized water, and the experimental group consisted of 35 different combination solutions. All treatments were performed in 3 independent biological replicates. Before treatment, the culture medium was removed, and the treatment culture medium containing each component was added. After culturing for 24 h, the activity was detected.

[0047] (1) The ROS assay method is as follows: Wash the cells, discard the culture medium, and wash twice slowly with PBS. Add DCFDA working solution (20 μM), incubate at 37℃ for 30 min, and protect from light. After incubation, discard the dye, wash twice with PBS, and detect the fluorescence intensity on a microplate reader (excitation wavelength Ex = 485 nm, emission wavelength Em = 535 nm). Calculate the relative ROS inhibition rate. The calculation formula is as follows: ROS inhibition rate (%) = (control group fluorescence - treatment group fluorescence) / control group fluorescence * 100%.

[0048] The results are shown in Table 2 and Figure 1. Compared with the blank group, the p < 0.01 of each group in Figure 2. Instruction manual, page 5 / 15, CN 121422187 A

[0049] Table 2 ROS inhibition rate results (n=3) Instruction manual, page 6 / 15, CN 121422187 A

[0050] As can be seen from the results in Table 2, each monomer group has a certain degree of ROS inhibition effect, but the differences between monomers are large and the inhibition rate is low. The ROS inhibition ability of each combination is significantly higher than that of each monomer. Through analysis of removing one group, it was found that the ROS inhibition rate decreased after removing any component. The ROS inhibition rate distribution of the random combination group is relatively dispersed, and the effect of some multi-component mixtures is not as good as that of the few-component combination, indicating that simple multi-component mixtures cannot bring stable antioxidant synergistic effects. Among them, group 26 showed the strongest ROS inhibition ability, with an average inhibition rate of 64.5%.

[0051] (2) Collagen I and SIRT1 expression analysis: NHDF cells were seeded in 12-well plates (1×10⁵ cells / well). After 24 h of adhesion under the same culture conditions, 35 groups of combinations were treated in the same manner as above. After 24 h of treatment, cell lysates were collected, and the protein expression levels of collagen I and SIRT1 were measured according to the ELISA kit instructions. The relative expression levels were calculated based on the average absorbance (OD value) of each group to reflect the anti-aging activity of the cells.

[0052] The results are shown in Table 3: Table 3 Statistical results of collagen I and SIRT1 levels (n=3, Mean ± SD) Instruction manual 7 / 15 page 9 CN 121422187 A Instruction manual 8 / 15 page 10 CN 121422187 A

[0053] The results in Table 3 show that after treatment with each group, the expression of collagen I and SIRT1 proteins in NHDF cells was upregulated to varying degrees, and the effect of the combination was significantly higher than that of any single group (p<0.01). It is worth noting that there are differences in the expression levels between different combinations, and some combinations even showed better effects than the combination of all components (group 12), indicating that the ratio and combination of components play a key role in synergistic activity, rather than just the cumulative effect of the number of components. Among them, group 26 can maximize the effect.The synergistic effect was demonstrated by the high OD value of collagen I (2.85) and the high OD value of SIRT1 (2.92), further verifying the key role of the ratio of group 26 in anti-aging activity.

[0054] Example 2 Optimization and verification of the anti-aging composition The composition screened in Example 1 (containing ergothioneine, coenzyme Q10, 3-SL, collagen tripeptide, NAD+ and glutathione) was optimized in terms of the concentration of each component to determine the optimal concentration ratio in order to maximize the inhibition of ROS and the expression of collagen I / SIRT1 in vitro, thereby improving the anti-aging activity.

[0055] The low, medium and high levels of each component were set according to the concentration range of each component, as shown in Table 4: Table 4 Concentration of each component at different levels (unit is mg / mL) Instruction manual 9 / 15 pages 11 CN 121422187 A

[0056] Experimental group setting: 27 different concentration combinations were set up using a 6-factor 3-level orthogonal design, with 3 biological replicates in each group.

[0057] Specific formulations are shown in Table 5: Table 5 Design Specifications for Different Concentration Combinations 10 / 15 Page 12 CN 121422187 A Specifications 11 / 15 Page 13 CN 121422187 A

[0058] ROS and collagen I and SIRT1 protein levels were tested according to the steps in Example 1.

[0059] The test results are shown in Table 6: Table 6 Anti-aging Activity Test Results (n=3, Mean ± SD)

[0060] The above results show that after NHDF cells were treated with 27 different concentration combinations, there were significant differences in ROS inhibition rate and collagen I and SIRT1 protein expression. Among them, the effects of groups 2, 5, 12 and 27 were significantly better than other groups, showing strong antioxidant and anti-aging activities. Group 5 showed the best effect, with a ROS inhibition rate of 81.7%, a collagen I OD value of 3.48, and a SIRT1 OD value of 3.51, which were significantly higher than other combinations (p<0.01). This indicates that the group ratio can exert the maximum synergistic effect, fully demonstrating the synergistic effect between the components.

[0061] Example 3 Anti-aging test in mice To further verify the anti-aging effect of the compound obtained in Example 2, C57BL / 6 mice, 8-10 weeks old, of any sex, were selected. The mice were allowed free access to standard feed and water under a constant temperature of 22±2℃ and a 12h light / dark cycle. After 1 week of acclimatization, the experiment was conducted. The groups included a blank control group and four experimental groups, of which experimental group 1 was group 2 in Example 2, experimental group 2 was group 5, experimental group 3 was group 12, and experimental group 4 was group 27. The experimental group mice were given a total dose of the composition of approximately 2.44 mg per mouse daily; the control group was given an equal volume of deionized water. All mice were administered the composition once daily by gavage for 4 consecutive weeks.

[0062] After drug administration, serum was separated from mouse blood, and antioxidant indicators in serum and tissues, including superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA), and catalase (CAT) levels, were detected. Experimental data are expressed as mean ± standard deviation (Mean ± SD), and one-way ANOVA was used for comparison between groups. Higher levels of SOD, GSH, and CAT indicate stronger antioxidant capacity; lower levels of MDA indicate less oxidative damage.

[0063] The results are shown in Figures 2-5. The antioxidant indicators in the serum of mice in the experimental groups all showed significant improvement. Specifically, experimental groups 1, 3, and 4 showed significantly higher levels of SOD, GSH, and CAT than the control group, while MDA levels decreased significantly (p<0.05). Among them, experimental group 2 performed best, with SOD reaching 66.8 U / mL, GSH at 9.7 μM, CAT at 73.5 U / mL, and MDA decreasing to 1.9 nmol / mL, significantly better than the other experimental groups (p<0.01).

[0064] Example 4 Clinical Skin Test To evaluate the effect of the composition of the present invention on the content of melanin and hemoglobin in the skin, 20 healthy female subjects aged 25-30 years were selected. The subjects were randomly divided into two groups: the experimental group took the formulation of group 5 in Example 2 (500 mg) daily, and the control group took an equal volume of placebo (deionized water) daily for 100 days. During the experiment, the subjects maintained their daily skin care habits, did not change to new skin care products, and tried to avoid strong sun exposure and prolonged outdoor activities. Before the experiment, the subjects cleansed their faces and rested quietly for 30 minutes in a constant temperature and humidity laboratory (approximately 22±2℃, relative humidity approximately 50%) to ensure stable skin condition.

[0065] Before the experiment and after 100 days of use, the melanin and hemoglobin test probes of the Mexameter® MX18 were used to measure the cheek area and record the melanin index (MI) and hemoglobin index (EI). The testing principle of the Mexameter® MX18 is a simplified reflectance spectrophotometry method, which uses specific wavelength light (568 nm green light, 660 nm red light, 880 nm infrared light) to irradiate the skin. The built-in photodetector receives the reflected light and calculates the amount of absorption and reflection by the skin to obtain the relative content of melanin and hemoglobin. The lower the MI value, the lower the skin melanin content, and the lower the EI value, the lower the skin hemoglobin content. Experimental data are expressed as mean ± standard deviation, and p < 0.05 is considered significant.

[0066] The test results are shown in Figure 6. After 100 days of continuous oral administration of the composition, the average MI of the facial skin of the subjects in the experimental group decreased from 282 to 230, a decrease of approximately 18.4% (p<0.01); while the control group only decreased from 280.3 to 273, with no significant difference (p>0.01).0.05). Regarding the hemoglobin index, the experimental group decreased from 288 to 247.8, a decrease of approximately 13.96% (p<0.01), while the control group showed no significant change (p>0.05). In addition, some subjects reported improvements in skin tone, a reduction in redness and dullness, and an increase in skin tone evenness. In summary, this composition has significant effects on improving skin metabolism, enhancing skin texture evenness, and delaying skin aging.

[0067] Example 5 Stability Evaluation of the Anti-aging Composition To verify the stability of the anti-aging composition, its physicochemical properties, content, and retention rate of active ingredients under different storage conditions were systematically evaluated. The anti-aging composition is the solution product obtained from the formulation of group 5 in Example 2, which does not contain preservatives or antioxidant additives. The samples were sealed and stored, and long-term and accelerated stability tests were conducted in a constant temperature and humidity chamber.

[0068] The specific method is as follows: The composition is dispensed into sealed glass containers and placed under the following three storage conditions: (1) Long-term storage conditions: 25±2℃, relative humidity 60±5%; (2) Accelerated storage conditions: 40±2℃, relative humidity 75±5%; (3) Low-temperature storage conditions: 5±3℃. Samples of group (1) were sampled and tested at 0 (initial), 1, 3, 6, 9, and 12 months of storage; samples of group (2) were sampled and tested at 0 (initial), 1, 2, and 3 months of storage; samples of group (3) were sampled and tested at 0 (initial), 6, and 12 months of storage; Samples of initial, long-term storage for 12 months, and accelerated storage for 3 months were selected for testing. The test items include: moisture content, content of each active ingredient, and total antioxidant capacity test. The contents of ergothioneine, coenzyme Q10, 3-SL, NAD+ and glutathione were determined by high performance liquid chromatography (HPLC), collagen tripeptide was detected by ultraviolet spectrophotometry, and the total antioxidant capacity was evaluated by DPPH free radical scavenging experiment.

[0069] The results are as follows: Table 7 Changes in the content of key components under long-term storage conditions (%)

[0070] Table 8 Changes in the content of key components under accelerated storage conditions (%)

[0071] Table 9 Changes in the content of key components under low-temperature storage conditions (%) Specification 14 / 15 pages 16 CN 121422187 A

[0072] Table 10 Results of total antioxidant capacity test

[0073] As can be seen from the above results, the composition of the present invention has excellent stability. Under long-term storage and accelerated storage conditions, the content of its main active ingredients remains stable, the antioxidant capacity decreases slightly, and the overall biological activity does not change significantly. Even without the addition of preservatives or antioxidant stabilizers, it remains stable for more than 12 months, fully demonstrating that the composition of the present invention has a stable structure and is suitable for long-term storage and application.

[0074] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention. Instruction manual, page 15 / 15, 17 CN 121422187 A, Figure 1, Figure 2; Instruction manual, Figure 1 / 3, page 18 CN 121422187 A, Figure 3, Figure 4; Instruction manual, Figure 2 / 3, page 19 CN 121422187 A, Figure 5, Figure 6; Instruction manual, Figure 3 / 3, page 20 CN 121422187 A Abstract: The present invention discloses an anti-aging composition, and a preparation method therefor and use thereof. The composition includes the components in parts by weight: 10-50 parts of ergothioneine, 5-25 parts of coenzyme Q10, 50-150 parts of 3-SL, 50-150 parts of collagen tripeptide, 100-500 parts of NAD+, and 50-150 parts of glutathione. The anti-aging composition exhibits significant synergistic anti-aging effects in both in vitro and in vivo experiments through the rational ratio of functional components, including ergothioneine, coenzyme Q10, 3-SL, collagen tripeptide, NAD+, and glutathione. The anti-aging composition enhances cellular antioxidant capacity, reduces reactive oxygen species levels, and promotes the expression of collagen I and SIRT1.Compared with a single component or a non-optimized combination, the composition has the significantly improved anti-aging effect.

Claims

1. An anti-aging composition, characterized in that, The composition comprises the following components by weight parts: Ergothioneine 5-80 parts; Coenzyme Q10 1-40 parts; 3-SL 30-200 parts; Collagen tripeptide 30-200 parts; NAD + 50-600 parts; Glutathione 30-200 parts.

2. The composition of claim 1, wherein, The composition comprises the following components by weight parts: Ergothioneine 10-50 parts; Coenzyme Q10 5-25 parts; 3-SL 50-150 parts; Collagen tripeptide 50-150 parts; NAD + 100-500 parts; Glutathione 50-150 parts.

3. The composition of claim 1, wherein, The composition comprises the following components by weight parts: ergothioneine 25 parts, coenzyme Q10 25 parts, 3-SL 75 parts, collagen tripeptide 110 parts, NAD + 160 parts, glutathione 80 parts.

4. The composition of claim 1, wherein, The composition comprises the following components by weight parts: ergothioneine 10 parts, coenzyme Q10 25 parts, 3-SL 75 parts, collagen tripeptide 75 parts, NAD + 250 parts, glutathione 80 parts.

5. The composition of claim 1, wherein The composition comprises the following components by weight parts: ergothioneine 10 parts, coenzyme Q10 50 parts, 3-SL 20 parts, collagen tripeptide 75 parts, NAD + 160 parts, glutathione 80 parts.

6. The composition of claim 1, wherein, The composition comprises the following components by weight parts: ergothioneine 50 parts, coenzyme Q10 50 parts, 3-SL 20 parts, collagen tripeptide 110 parts, NAD + 160 parts, glutathione 80 parts.

7. The composition of claim 1, wherein, The composition is any one of oral liquid preparation, capsule, granule, tablet or lyophilized powder.

8. The composition of claim 1, wherein, The composition further comprises any one or more of excipient, stabilizer, antioxidant, solubilizer or buffer.

9. Process for the preparation of a composition according to any one of claims 1 to 8, characterized in that, The method comprises the following steps: weighing each component by weight parts, adding appropriate amount of purified water, and mixing uniformly by magnetic stirring or ultrasonic until completely dissolved to obtain the composition solution.

10. Use of the composition of any one of claims 1-8 in the preparation of an anti-oxidation or anti-aging product.

Images